Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health has nominated Richard Jelinek for election to its Board of Directors at the upcoming annual meeting scheduled for June 8, 2023. Jelinek, who is a managing partner at Czech One Capital Partners, has extensive experience in the health care sector, including executive roles at Aetna and CVS Health. His appointment coincides with the departure of current board member David Farner and former Chairman Frank Williams, both set to leave the board in June 2023. Evolent's leadership believes Jelinek's expertise will enhance the board's perspectives and support the company’s mission in value-based specialty care. The board expressed gratitude for the contributions of Farner and Williams, emphasizing the importance of evolving governance.
Summary not available.
Evolent Health (NYSE: EVH) announced on March 29, 2023, an agreement with Centene Corporation (NYSE: CNC) to enhance its Technology and Services solution for oncology care. This partnership will extend Evolent's oncology services to Centene’s Medicare Advantage members across the nation, deepening their existing collaboration in the specialty care market. Both companies aim to optimize oncology outcomes while managing costs effectively. Evolent's established platform, backed by scientific advisory boards, focuses on clinical quality and financial accountability, ensuring improved care delivery for patients.
Evolent Health (NYSE: EVH) announced participation in several upcoming investor conferences. Chief Financial Officer John Johnson and Vice President of Investor Relations Seth Frank will represent the company. Details include:
- March 7, 2023: Cowen 43rd Annual Healthcare Conference in Boston at 10:30 a.m. ET.
- March 13, 2023: Annual Jefferies Value-Based Healthcare Summit in Miami Beach (no webcast).
- March 14, 2023: Barclays Global Healthcare Conference in Miami Beach at 3:35 p.m. ET.
Webcast recordings will be available on the investor relations section of Evolent's website. Evolent Health focuses on clinical and administrative solutions that improve health care affordability and accessibility.
Evolent Health (NYSE: EVH) reported Q4 and full-year 2022 financial results, showing significant growth. Q4 revenue reached $382.4 million, up 54.0% year-over-year, while full-year revenue totaled $1.35 billion, a 48.9% increase. Despite revenue growth, the company faced a net loss of $11.3 million for Q4, resulting in a net loss margin of (3.0)%. Total Lives on Platform expanded to 20.6 million. For 2023, Evolent secured new partnerships, including a significant sale expected to generate over $250 million in revenue for 2024. The company anticipates first-quarter revenue between $420 million and $440 million and full-year revenue of approximately $1.92 to $1.96 billion.
Evolent Health, Inc. (NYSE: EVH) has announced that it will release its fourth quarter 2022 financial results on February 22, 2023, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Shareholders and interested parties can listen to the call by dialing 855.940.9467 for domestic calls or 412.317.6034 for international access, referencing the Evolent Health call.
An audio playback will be available on the company's investor relations website for 90 days post-call. Evolent Health is known for delivering clinical and administrative solutions that enhance health care affordability and efficiency.
Evolent Health, Inc. (NYSE: EVH) announced participation in investor conferences featuring CEO Seth Blackley, CFO John Johnson, and VP Seth Frank. Key events include the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:30 a.m. ET and the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 4:30 p.m. ET. A live audio webcast will be available on Evolent's Investor Relations website. Evolent Health focuses on improving healthcare delivery through clinical and administrative solutions.
Evolent Health announced its agreement to acquire NIA, a specialty benefit management organization owned by Centene, for $650 million. The acquisition, set to close in mid-2023, is expected to add $85 million in adjusted EBITDA by 2024 and enhance Evolent’s value-based specialty care leadership. The deal diversifies Evolent's revenue base and increases cross-selling opportunities from $16 billion to $50 billion. The NIA acquisition will maintain Evolent's strong balance sheet and is projected to immediately improve cash flow and adjusted EBITDA margins.
Evolent Health, Inc. (EVH) reported a robust third quarter for 2022, generating $352.6 million in revenue, a 58.5% increase year-over-year. The company achieved a net income of $2.1 million with a margin of 0.6%, alongside an Adjusted EBITDA of $28.1 million and an 8.0% margin. Total lives on the platform reached 19.5 million. Evolent's new partnerships and acquisitions reflect sustained growth and innovation. For Q4 2022, revenue is projected between $361.0 million and $381.0 million, with full-year revenue guidance of $1.33 billion to $1.35 billion.
Evolent Health, Inc. (NYSE: EVH) has announced it will release its third quarter 2022 operating results on November 2, 2022, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Interested parties can join the call by dialing 855.940.9467 or 412.317.6034 for international access. An audio playback will be available on Evolent's investor relations website for 90 days post-call. Evolent Health focuses on delivering clinical and administrative solutions to improve healthcare efficiency and affordability.